Conclusion
These preliminary data suggest that NOACs are as safe and effective compared to VKA in patients with HCM undergoing catheter ablation for AF.
Disclosures and Conflicts of Interest – AC has received educational grants from Boston Scientific and Abbott; RJS has had research agreements and speaker fees from Abbott, Medtronic, Boston Scientific, and Biosense Webster; PDL has received educational grants from Medtronic and Boston Scientific & is supported by UCL/UCLH Biomedicine NIHR and Barts BRC; MF has received speaker fees from Biotronik and Medtronic, and owns stocks of Epicardio ltd. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.